Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Case by Case: Optimizing Dual Immune Checkpoint Inhibitor Combination Therapies in Advanced Driver-Negative Non–Small Cell Lung Cancer 

6 chapters
Play All
90 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Struggling to navigate the latest immunotherapy options for advanced NSCLC? This online CME program delves into optimizing dual immune checkpoint inhibitor therapy for patients with driver-negative advanced NSCLC. Learn how to leverage recent clinical trial data and patient characteristics to individualize treatment for the best possible outcomes, including for those with challenging brain metastases.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Patrick Forde, MBBCh
    Professor
    Johns Hopkins University
    Baltimore, MD 

    Dr. Forde has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: AstraZeneca, BMS, BioNTech, Novartis, Regeneron, Nextpoint
    Consulting Fees: Ascendis, AstraZeneca, BMS, Curevac, Novartis, Regeneron, G1, Genelux, Genentech, Gritstone, Merck, Janssen, F Star, Sanofi,  Amgen, Fosun, Teva, Synthekine, Flame, Iteos, Tavotek, Teva

    Faculty:
    Jarushka Naidoo, MBBCh, MHS
    Professor of Oncology
    Beaumont Hospital Dublin
    RCSI University of Health Sciences
    Dublin, Ireland

    Dr. Naidoo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Bristol Myers Squibb, AstraZeneca, Roche, Mirati, Amgen
    Consulting Fees: Bristol Myers Squibb, AstraZeneca, Roche, Mirati, Amgen, Takeda, Pfizer

    Reviewers/Content Planners/Authors:

    • Robert Garris has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Victor Ocana has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Bing-E Xu has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply the latest evidence to treatment of patients with advanced NSCLC who would benefit from anti-PD-1/PD-L1 plus anti-CTLA-4 inhibitor combination therapies, incorporating treatment-specific and patient-related characteristics  
    • Apply current guidelines and recent evidence to treating patients with metastatic NSCLC with brain metastases and without actionable driver mutations 
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists and pathologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with non–small cell lung cancer.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until July 16, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.50 contact hours/0.15 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-093-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from Bristol Meyers Squibb and AstraZeneca.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    Struggling to navigate the latest immunotherapy options for advanced NSCLC? This online CME program delves into optimizing dual immune checkpoint inhibitor therapy for patients with driver-negative advanced NSCLC. Learn how to leverage recent clinical trial data and patient characteristics to individualize treatment for the best possible outcomes, including for those with challenging brain metastases.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Patrick Forde, MBBCh
    Professor
    Johns Hopkins University
    Baltimore, MD 

    Dr. Forde has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: AstraZeneca, BMS, BioNTech, Novartis, Regeneron, Nextpoint
    Consulting Fees: Ascendis, AstraZeneca, BMS, Curevac, Novartis, Regeneron, G1, Genelux, Genentech, Gritstone, Merck, Janssen, F Star, Sanofi,  Amgen, Fosun, Teva, Synthekine, Flame, Iteos, Tavotek, Teva

    Faculty:
    Jarushka Naidoo, MBBCh, MHS
    Professor of Oncology
    Beaumont Hospital Dublin
    RCSI University of Health Sciences
    Dublin, Ireland

    Dr. Naidoo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Bristol Myers Squibb, AstraZeneca, Roche, Mirati, Amgen
    Consulting Fees: Bristol Myers Squibb, AstraZeneca, Roche, Mirati, Amgen, Takeda, Pfizer

    Reviewers/Content Planners/Authors:

    • Robert Garris has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Victor Ocana has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Bing-E Xu has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply the latest evidence to treatment of patients with advanced NSCLC who would benefit from anti-PD-1/PD-L1 plus anti-CTLA-4 inhibitor combination therapies, incorporating treatment-specific and patient-related characteristics  
    • Apply current guidelines and recent evidence to treating patients with metastatic NSCLC with brain metastases and without actionable driver mutations 
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists and pathologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with non–small cell lung cancer.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until July 16, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.50 contact hours/0.15 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-093-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by independent educational grants from Bristol Meyers Squibb and AstraZeneca.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule5 Dec 2024